<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004311</url>
  </required_header>
  <id_info>
    <org_study_id>ID-064-107</org_study_id>
    <secondary_id>2021-001522-21</secondary_id>
    <nct_id>NCT05004311</nct_id>
  </id_info>
  <brief_title>The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics</brief_title>
  <official_title>An Open-label, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cenerimod After Single-dose Administration in Subjects With Severe Renal Impairment and Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the PK of cenerimod in participants with severe renal impairment as compared&#xD;
      to healthy control participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of cenerimod</measure>
    <time_frame>Total duration: up to 52 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC from 0 to infinity) of cenerimod</measure>
    <time_frame>Total duration: up to 52 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of cenerimod</measure>
    <time_frame>Total duration: up to 52 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The time to reach Cmax (tmax) of cenerimod</measure>
    <time_frame>Total duration: up to 52 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t½) of cenerimod</measure>
    <time_frame>Total duration: up to 52 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance (CL/F) of cenerimod</measure>
    <time_frame>Total duration: up to 52 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent of cenerimod protein plasma binding (PPB)</measure>
    <time_frame>Total duration: up to 52 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of cenerimod</measure>
    <time_frame>Total duration: up to 52 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total lymphocyte count count.</measure>
    <time_frame>Total duration: up to 66 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at each time point of measurement in electrocardiogram QT interval</measure>
    <time_frame>Total duration: up to 66 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Total duration: up to 66 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic and diastolic blood pressure (in the supine position)</measure>
    <time_frame>Total duration: up to 66 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal laboratory test results</measure>
    <time_frame>Total duration: up to 66 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Group A (severe renal function impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight (8) participants with severe renal impairment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (healthy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight (8) control participants, matched to the 8 severe renal impaired participants enrolled in Group A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenerimod</intervention_name>
    <description>A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions</description>
    <arm_group_label>Group A (severe renal function impairment)</arm_group_label>
    <arm_group_label>Group B (healthy)</arm_group_label>
    <other_name>ACT-334441</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in a language understandable to the participant prior to any&#xD;
             study-mandated procedure.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening, a negative urine pregnancy test on Day -1, and agree to consistently and&#xD;
             correctly use a highly effective method of contraception.&#xD;
&#xD;
          -  Women of non-childbearing potential.&#xD;
&#xD;
          -  Body mass index of 18.0 to 35.0 kg/m2 (inclusive) at Screening&#xD;
&#xD;
          -  Negative SARS-CoV-2 reverse transcription polymerase chain reaction test on Day -1.&#xD;
&#xD;
        Additional inclusion criteria for participants with severe renal impairment&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) at screening using the Modification of&#xD;
             Diet in Renal Disease formula less-than 30 mL/min/1.73 m2 for participants with renal&#xD;
             impairment. The eGFR value should be confirmed on Day -1.&#xD;
&#xD;
          -  Systolic blood pressure (SBP) 100 to 180 mmHg, diastolic BP (DBP) 50 to 105 mmHg, and&#xD;
             pulse rate 60 to 100 bpm (inclusive), on Day 1 pre-dose.&#xD;
&#xD;
          -  Stable concomitant medications for at least 3 weeks prior to screening and up to Day&#xD;
             1.&#xD;
&#xD;
          -  Aspartate aminotransferase and alanine aminotransferase above the upper limit of&#xD;
             normal.&#xD;
&#xD;
          -  Clinically relevant findings in clinical laboratory tests (hematology, clinical&#xD;
             chemistry, and urinanalysis) except for those related to renal impairment at Screening&#xD;
             and on Day-1.&#xD;
&#xD;
        Additional inclusion criteria for control participants&#xD;
&#xD;
          -  eGFR at Screening using the Modification of Diet in Renal Disease formula of ≥ 90&#xD;
             mL/min/1.73 m2.&#xD;
&#xD;
          -  SBP 90 to 139 mmHg, DBP 60 to 89 mmHg, and pulse rate 60 to 99 bpm, measured on the&#xD;
             same arm, after 5 min in the supine position at screening and on Day 1 pre-dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Participation in a clinical study involving study treatment administration within 3&#xD;
             months prior to screening or participation in more than 2 clinical studies within 1&#xD;
             year prior to Screening.&#xD;
&#xD;
          -  Previous exposure to cenerimod.&#xD;
&#xD;
          -  Known hypersensitivity to any excipients of the treatment formulation.&#xD;
&#xD;
          -  Clinically relevant abnormalities on a 12-lead electrocardiogram at Screening and Day&#xD;
             -1.&#xD;
&#xD;
          -  Previous treatment with anti-arrhythmic medications of class Ia or III within 2 weeks&#xD;
             or 5 half-lives, whichever is longer, prior to study treatment administration.&#xD;
&#xD;
          -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition, which might interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the study treatment except for renal disease,&#xD;
             appendectomy, herniotomy, or cholecystectomy.&#xD;
&#xD;
          -  Aspartate aminotransferase and alanine aminotransferase above the upper limit of&#xD;
             normal.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at Screening.&#xD;
&#xD;
        Additional exclusion criteria for participants with severe renal impairment:&#xD;
&#xD;
          -  Presence of severe cardiac disease.&#xD;
&#xD;
          -  End-stage renal disease that requires dialysis.&#xD;
&#xD;
          -  History of severe renal artery stenosis.&#xD;
&#xD;
          -  Serum potassium concentration &gt; 5.5 mmol/L.&#xD;
&#xD;
          -  Presence of unstable diabetes mellitus.&#xD;
&#xD;
          -  Strict fluid restriction.&#xD;
&#xD;
          -  Clinically relevant findings in clinical laboratory tests (hematology, clinical&#xD;
             chemistry, and urinalysis) except for those related to renal impairment at Screening&#xD;
             and on Day -1.&#xD;
&#xD;
        Additional exclusion criteria for control participants&#xD;
&#xD;
          -  Clinically relevant findings on the physical examination at Screening.&#xD;
&#xD;
          -  Clinically relevant findings in clinical laboratory tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Disclosure Desk</last_name>
    <phone>+41 58 844 1977</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BlueClinical Phase 1 Hospital de Prelado</name>
      <address>
        <city>Porto</city>
        <zip>4250-449</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

